Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers

The potential to use biomarkers for identifying patients that are more likely to benefit or experience an adverse reaction in response to a given therapy, and thereby better match patients with therapies, is anticipated to have a major effect on both clinical practice and the development of new drugs and diagnostics. In this article, we consider current and emerging examples in which therapies are matched with specific patient population characteristics using clinical biomarkers — which we call stratified medicine — and discuss the implications of this approach to future product development strategies and market structures.

[1]  J. Verweij,et al.  Influence of Genetic Variants in UGT1A1 and UGT1A9 on the In Vivo Glucuronidation of SN‐38 , 2004, Journal of clinical pharmacology.

[2]  H. Grabowski,et al.  Longer Patents for Increased Generic Competition: The Waxman-Hatch Act after One Decade , 1997 .

[3]  R. W. Hansen,et al.  The price of innovation: new estimates of drug development costs. , 2003, Journal of health economics.

[4]  R. Frank,et al.  New estimates of drug development costs. , 2003, Journal of health economics.

[5]  V. Mooser,et al.  The APOE locus and the pharmacogenetics of lipid response , 2002, Current opinion in lipidology.

[6]  Tommy F. Liu,et al.  HIV-1 Protease and reverse-transcriptase mutations: correlations with antiretroviral therapy in subtype B isolates and implications for drug-resistance surveillance. , 2005, The Journal of infectious diseases.

[7]  J. Verweij,et al.  Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38 , 2004 .

[8]  J. Minna,et al.  Chasing mutations in the epidermal growth factor in lung cancer. , 2005, The New England journal of medicine.

[9]  Alex Matter,et al.  Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug , 2002, Nature Reviews Drug Discovery.

[10]  N. Agnanti,et al.  Approaching the dilemma between prophylactic bilateral mastectomy or oophorectomy for breast and ovarian cancer prevention in carriers ofBRCA1 orBRCA2 mutations , 2002, Annals of Surgical Oncology.

[11]  A. Marian,et al.  Pharmacogenetic study of statin therapy and cholesterol reduction. , 2005, Current atherosclerosis reports.

[12]  Jonathan J. Lewis,et al.  Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  G. Taylor,et al.  Determinants of Variable Response to Statin Treatment in Patients With Refractory Familial Hypercholesterolemia , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[14]  H. Burstein,et al.  The distinctive nature of HER2-positive breast cancers. , 2005, The New England journal of medicine.